1. Home
  2. VSTM vs NNNN Comparison

VSTM vs NNNN Comparison

Compare VSTM & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Verastem Inc.

VSTM

Verastem Inc.

HOLD

Current Price

$5.89

Market Cap

395.4M

Sector

Health Care

ML Signal

HOLD

Logo Anbio Biotechnology Class A Ordinary Shares

NNNN

Anbio Biotechnology Class A Ordinary Shares

HOLD

Current Price

$9.45

Market Cap

417.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VSTM
NNNN
Founded
2010
2021
Country
United States
Germany
Employees
N/A
27
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
395.4M
417.8M
IPO Year
2011
N/A

Fundamental Metrics

Financial Performance
Metric
VSTM
NNNN
Price
$5.89
$9.45
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$16.50
N/A
AVG Volume (30 Days)
3.2M
45.3K
Earning Date
05-07-2026
04-07-2026
Dividend Yield
N/A
N/A
EPS Growth
17.49
N/A
EPS
N/A
N/A
Revenue
$30,914,000.00
N/A
Revenue This Year
$282.64
N/A
Revenue Next Year
$72.25
N/A
P/E Ratio
N/A
$446.57
Revenue Growth
209.14
N/A
52 Week Low
$3.43
$8.30
52 Week High
$11.25
$54.90

Technical Indicators

Market Signals
Indicator
VSTM
NNNN
Relative Strength Index (RSI) 67.17 26.66
Support Level $5.53 $8.30
Resistance Level $6.48 $30.21
Average True Range (ATR) 0.47 1.47
MACD 0.11 0.31
Stochastic Oscillator 85.31 18.00

Price Performance

Historical Comparison
VSTM
NNNN

About VSTM Verastem Inc.

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).

Share on Social Networks: